“PROTAC 6”
IAP-based selective RIPK2 degrader prolonged PD w/ 0.15 mpk SC Q3D dosing E3 binder switch and property-based opt. Commun. Biol., Mar. 20, 2020 GlaxoSmithKline, Stevenage, UK / PMCC
Molecules of the Month - 2020 Molecules of the Year Nominees